Form 4: Akero Therapeutics CFO Sells Shares to Cover Tax Obligations

Akero Therapeutics' Chief Financial Officer, William Richard White, sold 2,804 shares of common stock for approximately $53.995 per share to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• William Richard White, Chief Financial Officer of Akero Therapeutics, Inc. (AKRO), reported a transaction involving the company's common stock.
• On June 10, 2025, Mr. White disposed of 2,804 shares of Akero Therapeutics common stock.
• The shares were sold at a weighted-average price of $53.995 per share, with individual transaction prices ranging from $53.337 to $54.00.
• This sale was executed as a 'sell-to-cover' transaction, which is an automatic and non-discretionary sale to satisfy tax withholding obligations associated with the vesting of restricted stock units.
• Following this reported transaction, Mr. White directly beneficially owns 59,155 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary transaction for tax purposes related to equity compensation, not indicative of management's view on the company's prospects or any operational changes.

Positives

• The transaction is a routine 'sell-to-cover' sale, indicating it was not a discretionary sale based on management's outlook but rather a standard procedure for tax compliance on equity compensation.
• The company has an established 'sell-to-cover' policy, which provides a clear mechanism for executives to manage tax liabilities from equity awards.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• "Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units."
• "The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person."
• "Such sales were automatic and not at the discretion of the Reporting Person."

Industry Context

This type of transaction, a 'sell-to-cover' to satisfy tax obligations on vested equity awards, is a common and routine occurrence for executives across all industries who receive a portion of their compensation in company stock or restricted stock units. It is not indicative of a change in company strategy or performance.

Comparison to Industry Standards

• The 'sell-to-cover' mechanism is a widely adopted practice by publicly traded companies to facilitate the tax obligations of their executives arising from equity compensation. This aligns with standard corporate governance practices for managing executive compensation and tax compliance.
• This transaction is comparable to similar tax-related sales by executives at other biotechnology or pharmaceutical companies, such as those seen at Gilead Sciences or Amgen, where equity compensation is a significant component of executive pay.

Corporate Governance

Related Party Transactions

• The sale of shares by the Chief Financial Officer to cover tax withholding obligations related to restricted stock units is a transaction between a related party (officer) and the company's securities, executed under a pre-existing 'sell-to-cover' policy.

Stakeholder Impact

• Shareholders: The transaction is a routine, non-discretionary sale for tax purposes and is unlikely to have a significant impact on shareholder sentiment or the company's valuation.
• Employees: The 'sell-to-cover' policy is a common practice for equity compensation, which may be relevant to other employees receiving similar awards.

Key Dates

Keywords

Akero Therapeutics, AKRO, Form 4, SEC filing, insider trading, stock sale, CFO, William Richard White, restricted stock units, tax withholding, sell-to-cover